Theriva™ Biologics Announces Upcoming Presentations at Medical Meetings

Core Insights - Theriva Biologics is set to present data on its therapeutic candidates VCN-01 and SYN-004 at major upcoming medical conferences, ESMO 2025 and IDWeek 2025, respectively [1][5]. Group 1: VCN-01 - VCN-01 (zabilugene almadenorepvec) is an oncolytic adenovirus that selectively replicates within tumor cells and degrades the tumor stroma, enhancing the efficacy of cancer treatments [3][9]. - The expanded data from the VIRAGE trial, focusing on metastatic pancreatic cancer (mPDAC), will be presented at ESMO 2025 [5][6]. - VCN-01 has been administered to 142 patients across various cancer types, including pancreatic, head and neck, ovarian, colorectal cancers, and retinoblastoma [3][9]. Group 2: SYN-004 - SYN-004 (ribaxamase) is an oral therapy designed to protect the gut microbiome from damage caused by IV beta-lactam antibiotics, thereby preventing Clostridioides difficile infection (CDI) and acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients [4][8][9]. - Interim blinded safety and pharmacokinetic data from the ongoing Phase 1b/2a trial of SYN-004 will be presented at IDWeek 2025 [5][7]. - A completed Phase 2b clinical trial with 412 patients demonstrated that SYN-004 effectively protected the gut microbiome and reduced the incidence of new colonization by pathogenic microorganisms [8].